Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial

[1] Malard F(2020)Treatment and unmet needs in steroid-refractory acute graft-versus-host disease Leukemia 34 1229-1240

[2] Huang XJ(2020)Reduced risk of chronic GVHD by low-dose rATG in adult matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies Ann Hematol 99 167-179

[3] Sim JPY(2018)Efficacy and safety of unmanipulated haploidentical related donor allogeneic peripheral blood stem cell transplantation in patients with relapsed/refractory acute myeloid leukemia Chin Med J 131 790-798

[4] Dou L(2017)Acute graft-versus-host disease - biologic process, prevention, and therapy N Engl J Med 377 2167-2179

[5] Hou C(2020)A monocentric study of steroid-refractory acute graft-versus-host disease treatment with tacrolimus and mTOR inhibitor Bone Marrow Transplant 55 86-92

[6] Ma C(2020)Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study Bone Marrow Transplant 55 641-648

[7] Li F(2020)Corticosteroid replacement by ruxolitinib in patients with acute GVHD experiencing severe steroid-induced side effects Bone Marrow Transplant 55 253-255

[8] Gao X(2018)The glucocorticoid receptor in recipient cells keeps cytokine secretion in acute graft-versus-host disease at bay Oncotarget 9 15437-15450

[9] Huang W(2018)Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials Immunotherapy 10 391-402

[10] Wang S(2019)Advances in understanding the pathogenesis of graft-versus-host disease Br J Haematol 187 563-572

[1] Malard F(2020)Treatment and unmet needs in steroid-refractory acute graft-versus-host disease Leukemia 34 1229-1240

[2] Huang XJ(2020)Reduced risk of chronic GVHD by low-dose rATG in adult matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies Ann Hematol 99 167-179

[3] Sim JPY(2018)Efficacy and safety of unmanipulated haploidentical related donor allogeneic peripheral blood stem cell transplantation in patients with relapsed/refractory acute myeloid leukemia Chin Med J 131 790-798

[4] Dou L(2017)Acute graft-versus-host disease - biologic process, prevention, and therapy N Engl J Med 377 2167-2179

[5] Hou C(2020)A monocentric study of steroid-refractory acute graft-versus-host disease treatment with tacrolimus and mTOR inhibitor Bone Marrow Transplant 55 86-92

[6] Ma C(2020)Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study Bone Marrow Transplant 55 641-648

[7] Li F(2020)Corticosteroid replacement by ruxolitinib in patients with acute GVHD experiencing severe steroid-induced side effects Bone Marrow Transplant 55 253-255

[8] Gao X(2018)The glucocorticoid receptor in recipient cells keeps cytokine secretion in acute graft-versus-host disease at bay Oncotarget 9 15437-15450

[9] Huang W(2018)Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials Immunotherapy 10 391-402

[10] Wang S(2019)Advances in understanding the pathogenesis of graft-versus-host disease Br J Haematol 187 563-572